Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy

19 Jan 2026 CW Team

The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio.

The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary.

This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026.

The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets.

Net proceeds will be utilised towards:

Payment to Viatris for acquisition of Biocon Biologics shares

Repayment of debt linked to the acquisition

Funding for redemption of compulsorily convertible debentures held by Biocon Biologics

General corporate purposes

The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025.

Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Biocon Limited has successfully completed a Qualified Institutions Placement (QIP), raising Rs 4.15 billion (approximately USD 460 million) through the issuance of 12,664,585 equity shares at an issue price of Rs 368.35 per share, including a premium of Rs 363.35. The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio. The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary. This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026. The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets. Net proceeds will be utilised towards: Payment to Viatris for acquisition of Biocon Biologics shares Repayment of debt linked to the acquisition Funding for redemption of compulsorily convertible debentures held by Biocon Biologics General corporate purposes The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025. Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Infrastructure Transport

06 Feb 2026

Second Mountain Tunnel Breakthrough in Palghar Advances High Speed Rail

The Mumbai-Ahmedabad high speed rail (MAHSR) project reached a milestone with the breakthrough of a mountain tunnel in Palghar, Maharashtra. Mountain tunnel MT-six measures 454 metres long and 14.4 metres wide and will accommodate up and down tracks. The breakthrough follows MT-five near Saphale on second January 2026 and the MT-six excavation was completed from both ends using the New Austrian Tunnelling Method. The ministry reported that the tunnelling was completed within 12 months. The New Austrian Tunnelling Method is favoured for its flexibility in complex geology and irregular tunnel s..

Infrastructure Transport

06 Feb 2026

Modi Government Pushes Atmanirbhar Container Drive With BCSL MoU

The Union Government advanced a plan to create an integrated, domestically anchored container ecosystem with the signing of a Memorandum of Understanding to establish the Bharat Container Shipping Line (BCSL). The MoU was signed by key agencies including the Shipping Corporation of India and Container Corporation of India alongside major port authorities and Sagarmala Finance Corporation Limited under the Ministry of Ports, Shipping and Waterways, in the presence of senior ministers. The initiative aligns with the Container Manufacturing Assistance Scheme announced in the Union Budget 2026–2..

Infrastructure Urban

06 Feb 2026

Ministry Reports Gains In Mobility For Marginalised Communities

The Ministry of Social Justice and Empowerment is implementing skill development, education and rehabilitation schemes to promote socio-economic mobility and sustainable livelihoods for marginalised and disadvantaged communities across the country. Programmes target Scheduled Castes, Other Backward Classes, Economically Weaker Sections, De-notified Tribes and Safai Karamcharis through specialised implementing corporations and empanelled training institutes. Pradhan Mantri Dakshata Aur Kushalta Sampann Hitgrahi Yojana, or PM-DAKSH, provided skill training and placement support through the Nati..